Budesonide/formoterol maintenance and reliever therapy versus conventional best standard treatment in asthma in an attempted ‘real life’ setting
| Autor: | Yao Lei, Tuomo Kava, Ragnar Dahle, Ulrik Søes-Petersen, Nanna Dam |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Pulmonary and Respiratory Medicine
Budesonide medicine.medical_specialty Exacerbation business.industry Standard treatment medicine.disease respiratory tract diseases law.invention Randomized controlled trial Budesonide/formoterol immune system diseases law Internal medicine Anesthesia Immunology and Allergy Medicine Formoterol Fumarate Formoterol business Genetics (clinical) medicine.drug Asthma |
| Zdroj: | The Clinical Respiratory Journal. 5:173-182 |
| ISSN: | 1752-6981 |
| DOI: | 10.1111/j.1752-699x.2010.00217.x |
| Popis: | Aims: The purpose of this study was to compare the efficacy of budesonide/formoterol maintenance and reliever therapy (Symbicort® SMART®, AstraZeneca AB, Sodertalje, Sweden) with conventional best standard treatment (CBST) in patients with persistent asthma in an attempted ‘real life’ setting. Methods: In total, 1835 patients from Denmark, Finland and Norway were randomized to 26 weeks treatment with budesonide/formoterol 160/4,5 µg twice daily plus budesonide/formoterol 160/4,5 µg for symptom relief or CBST according to the Global Initiative for Asthma guidelines. The study was randomized, open-label and designed to reflect ‘real life’ asthma management. Efficacy variables were time to first severe asthma exacerbation, rate of severe asthma exacerbations, asthma control (Asthma Control Questionnaire-5) and use of inhaled glucocorticosteroids (IGCS). Results: Treatment with budesonide/formoterol maintenance and reliever therapy led to a 21% reduction in time to first severe asthma exacerbation compared with CBST, although not statistically significant (hazard ratio 0.794, P = 0.189). A trend towards a reduction in the rate of severe exacerbations in the budesonide/formoterol maintenance and reliever therapy group was observed (16 vs 22 events/100 patient years; P = 0.058). The percentage of patients with well-controlled asthma increased significantly among those treated with budesonide/formoterol maintenance and reliever therapy compared with CBST (45% vs 40%; odds ratio 1.39; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|